ArticleThe Journal of molecular diagnostics : JMD2011
A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers.
Article in The Journal of molecular diagnostics : JMD, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- Evaluation of SNaPshot and Sanger sequencing for the detection ofEcancermedicalscience · 2024Article
- An innovative single-base extension method for synchronous detection of point mutations and MSI status in colorectal cancer.Cancer medicine · 2023Article
- The Sensitivity and Specificity of Novel Primers for Detection of BRAFV600E Mutation.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- An enzymatic on/off switch-mediated assay for KRAS hotspot point mutation detection of circulating tumor DNA.Journal of clinical laboratory analysis · 2020Article
- Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC).Diagnostics (Basel, Switzerland) · 2019Review
- KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015.Heliyon · 2019Article
- A novel RFLP-ARMS TaqMan PCR-based method for detecting the BRAF V600E mutation in melanoma.Oncology letters · 2018Article
- Mutation analysis of the EGFR pathway genes,Oncotarget · 2018Article
- Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer.Diagnostics (Basel, Switzerland) · 2017Article
- Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.American journal of clinical pathology · 2016Article
- The value of KRAS mutation testing with CEA for the diagnosis of pancreatic mucinous cysts.Endoscopy international open · 2016Article
- Assessment of high resolution melt analysis feasibility for evaluation of beta-globin gene mutations as a reproducible, cost-efficient and fast alternative to the present conventional method.Advanced biomedical research · 2016Article
- Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective.BioMed research international · 2016Review
- Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma.Chinese journal of cancer · 2015Article
- A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.Targeted oncology · 2015Article
- Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.Molecular diagnosis & therapy · 2014Article
- Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas.Diagnostic pathology · 2013Article
- Tumour molecular profiling for deciding therapy-the French initiative.Nature reviews. Clinical oncology · 2012Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The analysis of KRAS mutations has become a prerequisite for anti-epidermal growth factor receptor therapy in patients with metastatic colorectal cancers. KRAS mutations are associated with resistance to treatment by monoclonal antibodies such as cetuximab and panitumumab and thus are correlated with a shorter progression-free survival. BRAF mutations also may play a role in treatment decisions. The widespread use of these targeted therapies has generated the need to develop cost-effective methods for routine KRAS and BRAF analysis. The aim of this study was to compare a multiplex SNaPshot assay with DNA sequencing and high-resolution melting analysis for identifying KRAS codons 12 and 13 and BRAF codon 600 mutations. Thus 110 routinely formalin-fixed and paraffin-embedded tissue blocks were tested by each method. The SNaPshot analysis detected KRAS and BRAF codon 600 mutations in, respectively, 34.5% (n = 38) and 10% (n = 11) of these tissue blocks. These results were confirmed by direct DNA sequencing and by high-resolution melting analysis. The costs and time constraints of each detection method were compared at the same time. In conclusion, our newly designed multiplex SNaPshot assay is a fast, inexpensive, sensitive, and robust technique for molecular diagnostic practices and patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.